Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Early Detection of Cancer | 13 | 2023 | 73 | 4.060 |
Why?
|
Lung Neoplasms | 22 | 2023 | 384 | 3.950 |
Why?
|
Mass Screening | 14 | 2023 | 225 | 3.530 |
Why?
|
Colorectal Neoplasms | 8 | 2023 | 208 | 2.810 |
Why?
|
Decision Making | 5 | 2022 | 180 | 2.670 |
Why?
|
Primary Health Care | 9 | 2022 | 181 | 2.070 |
Why?
|
Internship and Residency | 5 | 2017 | 283 | 1.480 |
Why?
|
Electronic Health Records | 4 | 2020 | 121 | 1.480 |
Why?
|
Students, Medical | 3 | 2022 | 121 | 1.250 |
Why?
|
Access to Information | 2 | 2019 | 12 | 1.230 |
Why?
|
Health Knowledge, Attitudes, Practice | 7 | 2017 | 327 | 1.160 |
Why?
|
Attitude of Health Personnel | 4 | 2016 | 163 | 1.110 |
Why?
|
Humans | 67 | 2023 | 29213 | 1.100 |
Why?
|
Computer-Assisted Instruction | 4 | 2015 | 21 | 1.070 |
Why?
|
Decision Support Techniques | 2 | 2019 | 104 | 1.000 |
Why?
|
Internal Medicine | 4 | 2017 | 45 | 0.950 |
Why?
|
Nursing Staff | 1 | 2022 | 4 | 0.850 |
Why?
|
Curriculum | 5 | 2022 | 196 | 0.850 |
Why?
|
Patient Education as Topic | 6 | 2012 | 252 | 0.840 |
Why?
|
Caregivers | 2 | 2020 | 94 | 0.830 |
Why?
|
Clinical Clerkship | 1 | 2022 | 41 | 0.820 |
Why?
|
Polymorphism, Genetic | 9 | 2007 | 196 | 0.810 |
Why?
|
Internet | 5 | 2019 | 158 | 0.800 |
Why?
|
Privacy | 1 | 2020 | 9 | 0.750 |
Why?
|
Steam | 1 | 2020 | 1 | 0.740 |
Why?
|
Fires | 1 | 2020 | 4 | 0.730 |
Why?
|
Philosophy | 2 | 2020 | 2 | 0.720 |
Why?
|
United States | 14 | 2020 | 3648 | 0.720 |
Why?
|
Hospitals | 1 | 2020 | 89 | 0.710 |
Why?
|
User-Computer Interface | 2 | 2019 | 34 | 0.680 |
Why?
|
Middle Aged | 31 | 2021 | 10868 | 0.670 |
Why?
|
Male | 39 | 2020 | 17872 | 0.670 |
Why?
|
Vulnerable Populations | 1 | 2018 | 25 | 0.640 |
Why?
|
Female | 38 | 2022 | 18236 | 0.640 |
Why?
|
Information Dissemination | 2 | 2016 | 42 | 0.630 |
Why?
|
Science | 1 | 2017 | 8 | 0.620 |
Why?
|
False Positive Reactions | 1 | 2017 | 25 | 0.620 |
Why?
|
Patient Preference | 2 | 2015 | 38 | 0.610 |
Why?
|
Health Literacy | 2 | 2015 | 26 | 0.610 |
Why?
|
Health Education | 2 | 2015 | 121 | 0.580 |
Why?
|
Medical Oncology | 1 | 2017 | 70 | 0.580 |
Why?
|
Laboratories | 1 | 2016 | 13 | 0.560 |
Why?
|
Glutathione Transferase | 3 | 2007 | 18 | 0.540 |
Why?
|
Historiography | 1 | 2015 | 1 | 0.540 |
Why?
|
Adult | 26 | 2023 | 8466 | 0.540 |
Why?
|
Mathematics | 1 | 2015 | 9 | 0.540 |
Why?
|
Alcohol-Related Disorders | 1 | 2015 | 22 | 0.530 |
Why?
|
Aged | 22 | 2021 | 9510 | 0.530 |
Why?
|
Physicians | 1 | 2017 | 135 | 0.520 |
Why?
|
Prejudice | 2 | 2013 | 45 | 0.490 |
Why?
|
Qualitative Research | 3 | 2022 | 142 | 0.490 |
Why?
|
Periodicals as Topic | 1 | 2015 | 95 | 0.480 |
Why?
|
Prostatic Neoplasms | 3 | 2014 | 441 | 0.470 |
Why?
|
Isoenzymes | 2 | 2003 | 63 | 0.460 |
Why?
|
Awareness | 1 | 2013 | 29 | 0.460 |
Why?
|
Smoking | 8 | 2022 | 439 | 0.430 |
Why?
|
Cataract | 1 | 2011 | 5 | 0.410 |
Why?
|
Androstadienes | 1 | 2011 | 17 | 0.410 |
Why?
|
Glaucoma | 1 | 2011 | 11 | 0.410 |
Why?
|
Albuterol | 1 | 2011 | 40 | 0.400 |
Why?
|
Bronchodilator Agents | 1 | 2011 | 82 | 0.390 |
Why?
|
Smoking Cessation | 2 | 2023 | 133 | 0.390 |
Why?
|
Colonoscopy | 2 | 2023 | 41 | 0.380 |
Why?
|
Tobacco Smoke Pollution | 3 | 2008 | 37 | 0.370 |
Why?
|
Blood Glucose Self-Monitoring | 2 | 2020 | 24 | 0.370 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 120 | 0.360 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 1365 | 0.350 |
Why?
|
Telemedicine | 2 | 2020 | 77 | 0.340 |
Why?
|
Drug Industry | 1 | 2008 | 14 | 0.330 |
Why?
|
Multimedia | 2 | 2005 | 12 | 0.330 |
Why?
|
Medically Uninsured | 1 | 2008 | 31 | 0.330 |
Why?
|
Logistic Models | 7 | 2020 | 729 | 0.330 |
Why?
|
Patient Participation | 2 | 2022 | 62 | 0.320 |
Why?
|
Patient Compliance | 2 | 2007 | 212 | 0.320 |
Why?
|
Drug Prescriptions | 1 | 2008 | 52 | 0.320 |
Why?
|
Breast Neoplasms | 1 | 2014 | 667 | 0.320 |
Why?
|
Academic Medical Centers | 2 | 2022 | 150 | 0.310 |
Why?
|
Retrospective Studies | 5 | 2020 | 3121 | 0.310 |
Why?
|
Schools, Medical | 2 | 2022 | 42 | 0.310 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2007 | 5 | 0.310 |
Why?
|
Drug Therapy | 1 | 2007 | 16 | 0.310 |
Why?
|
Health Benefit Plans, Employee | 1 | 2007 | 14 | 0.310 |
Why?
|
Feasibility Studies | 3 | 2019 | 267 | 0.300 |
Why?
|
Health Expenditures | 1 | 2007 | 61 | 0.290 |
Why?
|
Tablets | 2 | 2022 | 10 | 0.290 |
Why?
|
History, 20th Century | 2 | 2017 | 68 | 0.290 |
Why?
|
North Carolina | 7 | 2016 | 1424 | 0.290 |
Why?
|
Pilot Projects | 6 | 2017 | 478 | 0.280 |
Why?
|
Population Surveillance | 1 | 2007 | 119 | 0.280 |
Why?
|
Risk Assessment | 4 | 2019 | 1312 | 0.280 |
Why?
|
Case-Control Studies | 12 | 2011 | 860 | 0.270 |
Why?
|
Aged, 80 and over | 13 | 2015 | 3726 | 0.270 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 871 | 0.260 |
Why?
|
Risk Factors | 14 | 2021 | 3547 | 0.260 |
Why?
|
Office Visits | 1 | 2005 | 71 | 0.250 |
Why?
|
Time Factors | 6 | 2019 | 2003 | 0.240 |
Why?
|
Government Programs | 1 | 2023 | 8 | 0.230 |
Why?
|
Clinical Competence | 2 | 2016 | 307 | 0.230 |
Why?
|
Tobacco Use Cessation | 1 | 2023 | 14 | 0.230 |
Why?
|
Occult Blood | 2 | 2017 | 9 | 0.230 |
Why?
|
Ambulatory Care Facilities | 3 | 2019 | 65 | 0.220 |
Why?
|
Program Evaluation | 5 | 2015 | 175 | 0.210 |
Why?
|
Interviews as Topic | 3 | 2016 | 249 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2003 | 142 | 0.210 |
Why?
|
Depression | 2 | 2022 | 383 | 0.200 |
Why?
|
Efficiency, Organizational | 2 | 2016 | 18 | 0.200 |
Why?
|
Educational Measurement | 2 | 2017 | 111 | 0.200 |
Why?
|
Focus Groups | 1 | 2022 | 104 | 0.200 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2020 | 1382 | 0.200 |
Why?
|
Prospective Studies | 4 | 2022 | 2027 | 0.200 |
Why?
|
Obesity | 3 | 2013 | 1068 | 0.200 |
Why?
|
Blood Glucose | 2 | 2020 | 467 | 0.190 |
Why?
|
Glutathione S-Transferase pi | 3 | 2007 | 6 | 0.190 |
Why?
|
Research Design | 2 | 2017 | 286 | 0.190 |
Why?
|
Activities of Daily Living | 1 | 2022 | 240 | 0.190 |
Why?
|
Influenza Vaccines | 1 | 2021 | 78 | 0.190 |
Why?
|
Odds Ratio | 5 | 2011 | 448 | 0.190 |
Why?
|
Delivery of Health Care | 1 | 2022 | 142 | 0.190 |
Why?
|
Adenocarcinoma | 1 | 2003 | 301 | 0.190 |
Why?
|
Poliovirus Vaccine, Inactivated | 1 | 2020 | 3 | 0.180 |
Why?
|
Fibroins | 1 | 2020 | 5 | 0.180 |
Why?
|
Knowledge | 1 | 2020 | 15 | 0.180 |
Why?
|
Endocrinology | 1 | 2019 | 2 | 0.180 |
Why?
|
Thermodynamics | 1 | 2020 | 45 | 0.180 |
Why?
|
Monitoring, Ambulatory | 1 | 2019 | 8 | 0.180 |
Why?
|
Temperature | 1 | 2020 | 55 | 0.180 |
Why?
|
Influenza, Human | 1 | 2021 | 122 | 0.180 |
Why?
|
Preventive Health Services | 1 | 2020 | 30 | 0.180 |
Why?
|
European Continental Ancestry Group | 4 | 2011 | 1131 | 0.180 |
Why?
|
History, 21st Century | 2 | 2020 | 48 | 0.180 |
Why?
|
Risk | 2 | 2017 | 290 | 0.170 |
Why?
|
Sex Factors | 4 | 2016 | 632 | 0.170 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 116 | 0.170 |
Why?
|
Evidence-Based Medicine | 2 | 2017 | 208 | 0.170 |
Why?
|
Disclosure | 1 | 2018 | 36 | 0.160 |
Why?
|
Hypoglycemic Agents | 1 | 2019 | 177 | 0.160 |
Why?
|
Electroencephalography | 2 | 2016 | 71 | 0.160 |
Why?
|
Drugs, Generic | 2 | 2008 | 13 | 0.160 |
Why?
|
Ambulatory Care | 1 | 2019 | 97 | 0.160 |
Why?
|
Socioeconomic Factors | 2 | 2011 | 394 | 0.160 |
Why?
|
Terminology as Topic | 1 | 2017 | 62 | 0.150 |
Why?
|
Patient Selection | 1 | 2019 | 257 | 0.150 |
Why?
|
Motor Cortex | 1 | 2016 | 12 | 0.150 |
Why?
|
Locomotion | 1 | 2016 | 31 | 0.150 |
Why?
|
Education, Medical | 1 | 2017 | 67 | 0.140 |
Why?
|
Choline Kinase | 1 | 2016 | 1 | 0.140 |
Why?
|
Clinical Laboratory Techniques | 1 | 2016 | 18 | 0.140 |
Why?
|
Genetic Predisposition to Disease | 3 | 2004 | 836 | 0.140 |
Why?
|
Drug Discovery | 1 | 2016 | 30 | 0.140 |
Why?
|
Atherosclerosis | 1 | 2021 | 698 | 0.140 |
Why?
|
Logic | 1 | 2015 | 2 | 0.130 |
Why?
|
England | 1 | 2015 | 4 | 0.130 |
Why?
|
Family Practice | 1 | 2015 | 47 | 0.130 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2015 | 9 | 0.130 |
Why?
|
Enzyme Inhibitors | 1 | 2016 | 162 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2006 | 93 | 0.130 |
Why?
|
Alcoholism | 1 | 2015 | 98 | 0.130 |
Why?
|
Health Surveys | 1 | 2015 | 191 | 0.130 |
Why?
|
Communication | 1 | 2016 | 122 | 0.130 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 1017 | 0.120 |
Why?
|
Drug Hypersensitivity | 1 | 2013 | 8 | 0.120 |
Why?
|
Prevalence | 1 | 2016 | 907 | 0.120 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2013 | 13 | 0.120 |
Why?
|
Peroxidase | 2 | 2004 | 33 | 0.120 |
Why?
|
Alcohol Drinking | 1 | 2016 | 246 | 0.120 |
Why?
|
Semantic Differential | 1 | 2013 | 6 | 0.120 |
Why?
|
Pneumonia, Bacterial | 1 | 2013 | 31 | 0.120 |
Why?
|
Urinary Tract Infections | 1 | 2013 | 36 | 0.110 |
Why?
|
African Americans | 3 | 2011 | 1373 | 0.110 |
Why?
|
Bacteremia | 1 | 2013 | 53 | 0.110 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 293 | 0.110 |
Why?
|
Data Collection | 2 | 2020 | 163 | 0.110 |
Why?
|
Social Marketing | 1 | 2012 | 14 | 0.100 |
Why?
|
Digital Rectal Examination | 2 | 2009 | 10 | 0.100 |
Why?
|
Genotype | 5 | 2007 | 735 | 0.100 |
Why?
|
MP3-Player | 1 | 2011 | 2 | 0.100 |
Why?
|
Warfarin | 1 | 2011 | 30 | 0.100 |
Why?
|
Incidence | 3 | 2011 | 1123 | 0.100 |
Why?
|
Drug Combinations | 1 | 2011 | 86 | 0.100 |
Why?
|
Urban Health Services | 1 | 2011 | 10 | 0.100 |
Why?
|
Community Health Centers | 1 | 2011 | 13 | 0.100 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 285 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 246 | 0.100 |
Why?
|
Program Development | 1 | 2011 | 85 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2012 | 114 | 0.100 |
Why?
|
Treatment Outcome | 3 | 2019 | 3108 | 0.100 |
Why?
|
Research | 1 | 2011 | 72 | 0.100 |
Why?
|
Databases, Factual | 1 | 2011 | 333 | 0.090 |
Why?
|
Patient Satisfaction | 1 | 2011 | 223 | 0.090 |
Why?
|
Health Promotion | 1 | 2012 | 220 | 0.090 |
Why?
|
Marketing of Health Services | 1 | 2008 | 4 | 0.080 |
Why?
|
Masculinity | 1 | 2008 | 3 | 0.080 |
Why?
|
Drug Costs | 1 | 2008 | 42 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2006 | 437 | 0.080 |
Why?
|
Medicaid | 1 | 2008 | 83 | 0.080 |
Why?
|
Pharmacogenetics | 1 | 2008 | 35 | 0.080 |
Why?
|
Formularies as Topic | 1 | 2007 | 3 | 0.080 |
Why?
|
Prescription Fees | 1 | 2007 | 6 | 0.080 |
Why?
|
Cost Sharing | 1 | 2007 | 10 | 0.080 |
Why?
|
Cost Control | 1 | 2007 | 17 | 0.080 |
Why?
|
Drug Utilization | 1 | 2007 | 47 | 0.080 |
Why?
|
Arsenic Poisoning | 1 | 2007 | 1 | 0.080 |
Why?
|
Health Behavior | 1 | 2009 | 216 | 0.070 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2003 | 9 | 0.070 |
Why?
|
Infant | 3 | 2016 | 973 | 0.070 |
Why?
|
Prognosis | 2 | 2008 | 1363 | 0.070 |
Why?
|
Polymerase Chain Reaction | 2 | 2003 | 172 | 0.070 |
Why?
|
Iron, Dietary | 1 | 2005 | 11 | 0.070 |
Why?
|
Calcium, Dietary | 1 | 2005 | 23 | 0.070 |
Why?
|
Zinc | 1 | 2005 | 32 | 0.070 |
Why?
|
Lung | 2 | 2023 | 233 | 0.070 |
Why?
|
Microcomputers | 1 | 2005 | 4 | 0.070 |
Why?
|
Attitude to Computers | 1 | 2005 | 7 | 0.070 |
Why?
|
North America | 1 | 2005 | 33 | 0.060 |
Why?
|
Australia | 1 | 2005 | 66 | 0.060 |
Why?
|
Europe | 1 | 2005 | 77 | 0.060 |
Why?
|
Follow-Up Studies | 2 | 2007 | 2114 | 0.060 |
Why?
|
Medical Records | 1 | 2005 | 68 | 0.060 |
Why?
|
Superoxide Dismutase | 1 | 2004 | 47 | 0.060 |
Why?
|
Health Services | 1 | 2005 | 35 | 0.060 |
Why?
|
Needs Assessment | 1 | 2005 | 66 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2007 | 206 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2005 | 160 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2005 | 638 | 0.060 |
Why?
|
Quality of Health Care | 1 | 2005 | 134 | 0.060 |
Why?
|
Respiratory Distress Syndrome, Adult | 1 | 2004 | 55 | 0.060 |
Why?
|
Attitude to Health | 1 | 2005 | 148 | 0.060 |
Why?
|
DNA Helicases | 1 | 2003 | 5 | 0.060 |
Why?
|
DNA Primers | 1 | 2003 | 87 | 0.060 |
Why?
|
Models, Biological | 1 | 2005 | 373 | 0.060 |
Why?
|
Self Disclosure | 1 | 2003 | 23 | 0.060 |
Why?
|
Serine | 1 | 2003 | 11 | 0.060 |
Why?
|
Codon | 1 | 2003 | 7 | 0.060 |
Why?
|
Genes, p53 | 1 | 2003 | 23 | 0.060 |
Why?
|
Arginine | 1 | 2003 | 17 | 0.060 |
Why?
|
Point Mutation | 1 | 2002 | 23 | 0.060 |
Why?
|
DNA-Binding Proteins | 1 | 2003 | 142 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2005 | 466 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 788 | 0.050 |
Why?
|
Propensity Score | 1 | 2022 | 34 | 0.050 |
Why?
|
Arylamine N-Acetyltransferase | 1 | 2002 | 1 | 0.050 |
Why?
|
Epoxide Hydrolases | 1 | 2002 | 5 | 0.050 |
Why?
|
Proteins | 1 | 2003 | 140 | 0.050 |
Why?
|
Transcription Factors | 1 | 2003 | 172 | 0.050 |
Why?
|
Silk | 1 | 2021 | 2 | 0.050 |
Why?
|
Needles | 1 | 2021 | 28 | 0.050 |
Why?
|
Food Supply | 1 | 2021 | 54 | 0.050 |
Why?
|
Computer Simulation | 1 | 2022 | 211 | 0.050 |
Why?
|
Nutrition Surveys | 1 | 2021 | 136 | 0.050 |
Why?
|
Drug Storage | 1 | 2020 | 3 | 0.050 |
Why?
|
Poliomyelitis | 1 | 2020 | 4 | 0.050 |
Why?
|
Antibodies, Neutralizing | 1 | 2020 | 17 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2020 | 14 | 0.050 |
Why?
|
Rats, Wistar | 1 | 2020 | 84 | 0.050 |
Why?
|
Educational Status | 2 | 2012 | 165 | 0.050 |
Why?
|
Adolescent | 4 | 2011 | 3265 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2020 | 56 | 0.040 |
Why?
|
Infant, Newborn | 2 | 2015 | 603 | 0.040 |
Why?
|
Social Environment | 1 | 2020 | 75 | 0.040 |
Why?
|
Survival Rate | 3 | 2008 | 795 | 0.040 |
Why?
|
Hospitalists | 1 | 1999 | 7 | 0.040 |
Why?
|
Workload | 1 | 1999 | 38 | 0.040 |
Why?
|
Animals | 2 | 2021 | 7302 | 0.040 |
Why?
|
Patients | 1 | 2018 | 46 | 0.040 |
Why?
|
Medicare | 1 | 2020 | 187 | 0.040 |
Why?
|
Age Factors | 3 | 2008 | 1110 | 0.040 |
Why?
|
Movement | 1 | 2016 | 41 | 0.040 |
Why?
|
Child Development | 1 | 2016 | 35 | 0.040 |
Why?
|
Cohort Studies | 3 | 2009 | 1694 | 0.040 |
Why?
|
Phosphorylcholine | 1 | 2016 | 5 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2016 | 11 | 0.030 |
Why?
|
Small Molecule Libraries | 1 | 2016 | 9 | 0.030 |
Why?
|
Crystallography, X-Ray | 1 | 2016 | 77 | 0.030 |
Why?
|
Medical History Taking | 1 | 2015 | 32 | 0.030 |
Why?
|
Rats | 1 | 2020 | 1604 | 0.030 |
Why?
|
Protein Binding | 1 | 2016 | 199 | 0.030 |
Why?
|
Models, Molecular | 1 | 2016 | 178 | 0.030 |
Why?
|
Cerebral Cortex | 1 | 2016 | 141 | 0.030 |
Why?
|
Mice | 1 | 2021 | 2372 | 0.030 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2015 | 33 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2015 | 72 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2015 | 116 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 641 | 0.030 |
Why?
|
Brain Mapping | 1 | 2015 | 182 | 0.030 |
Why?
|
beta-Lactams | 1 | 2013 | 5 | 0.030 |
Why?
|
Apoptosis | 1 | 2016 | 337 | 0.030 |
Why?
|
Empirical Research | 1 | 2013 | 8 | 0.030 |
Why?
|
Gram-Negative Bacteria | 1 | 2013 | 7 | 0.030 |
Why?
|
Tetracycline | 1 | 2013 | 11 | 0.030 |
Why?
|
Fluoroquinolones | 1 | 2013 | 10 | 0.030 |
Why?
|
Radiography | 1 | 2015 | 353 | 0.030 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2013 | 15 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 681 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2016 | 573 | 0.030 |
Why?
|
Gene Frequency | 2 | 2004 | 225 | 0.030 |
Why?
|
Culture | 1 | 2013 | 38 | 0.030 |
Why?
|
Statistics as Topic | 2 | 2003 | 107 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2013 | 273 | 0.030 |
Why?
|
Alleles | 2 | 2003 | 251 | 0.030 |
Why?
|
Confidence Intervals | 2 | 2002 | 141 | 0.030 |
Why?
|
Reference Values | 2 | 2002 | 224 | 0.030 |
Why?
|
International Normalized Ratio | 1 | 2011 | 5 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2011 | 16 | 0.030 |
Why?
|
Physician-Patient Relations | 1 | 2013 | 169 | 0.020 |
Why?
|
Mentors | 1 | 2011 | 29 | 0.020 |
Why?
|
Education, Medical, Undergraduate | 1 | 2012 | 84 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 546 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2013 | 726 | 0.020 |
Why?
|
Anticoagulants | 1 | 2011 | 122 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2011 | 231 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2009 | 61 | 0.020 |
Why?
|
Attitude | 1 | 2008 | 37 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 26 | 0.020 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 18 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2008 | 126 | 0.020 |
Why?
|
Arsenic | 1 | 2007 | 5 | 0.020 |
Why?
|
Causality | 1 | 2007 | 39 | 0.020 |
Why?
|
Water Supply | 1 | 2007 | 10 | 0.020 |
Why?
|
India | 1 | 2007 | 61 | 0.020 |
Why?
|
Regression Analysis | 1 | 2007 | 274 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2006 | 281 | 0.020 |
Why?
|
DNA Adducts | 1 | 2005 | 13 | 0.020 |
Why?
|
Safety | 1 | 2005 | 73 | 0.020 |
Why?
|
Algorithms | 1 | 2008 | 463 | 0.020 |
Why?
|
Young Adult | 1 | 2011 | 2413 | 0.020 |
Why?
|
Child, Preschool | 1 | 2008 | 1168 | 0.020 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2003 | 1 | 0.010 |
Why?
|
Boston | 1 | 2003 | 16 | 0.010 |
Why?
|
Genetic Code | 1 | 2003 | 2 | 0.010 |
Why?
|
Massachusetts | 1 | 2003 | 28 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2002 | 53 | 0.010 |
Why?
|
Genetic Markers | 1 | 2003 | 122 | 0.010 |
Why?
|
Probability | 1 | 2002 | 150 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2002 | 212 | 0.010 |
Why?
|
Sex Distribution | 1 | 2002 | 186 | 0.010 |
Why?
|
Child | 1 | 2008 | 2221 | 0.010 |
Why?
|
Age Distribution | 1 | 2002 | 198 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2002 | 514 | 0.010 |
Why?
|
Bed Occupancy | 1 | 1999 | 1 | 0.010 |
Why?
|
Hospital Bed Capacity | 1 | 1999 | 5 | 0.010 |
Why?
|
Benchmarking | 1 | 1999 | 25 | 0.010 |
Why?
|
Forecasting | 1 | 1999 | 133 | 0.010 |
Why?
|
Models, Statistical | 1 | 1999 | 164 | 0.010 |
Why?
|
Referral and Consultation | 1 | 1999 | 113 | 0.010 |
Why?
|